GX-01

Dedicated to Keeping Yo Healthy and Happy.

A Next-Generation CAR-T Therapy

GX-01 is Cambridge GenetiX’s lead Anti-CD19 CAR-T therapy, engineered to deliver enhanced safety, precision, and therapeutic durability. Designed using advanced cellular engineering and automated manufacturing platforms, GX-01 represents a next-generation approach to CAR-T treatment for patients with unmet medical needs.

Fully Humanized CAR Architecture

GX-01 utilizes a fully humanized Anti-CD19 single-chain variable fragment (scFv) combined with a second-generation chimeric antigen receptor design. This architecture is optimized to improve target specificity, reduce immunogenicity, and enhance overall therapeutic performance.

Targeted Immune Activation

GX-01 CAR-T cells are engineered to recognize and bind CD19-expressing cells. Upon engagement, the CAR signaling domains activate the patient’s immune cells, enabling targeted elimination of diseased cells while maintaining controlled immune activation.

Built for Scalability and Consistency

Compassionate Care – Patient er well-being first.

GX-01 is produced using Cambridge GenetiX’s modular and automated manufacturing systems. These platforms are designed to support reproducibility, quality control, and clinical scalability, enabling efficient production aligned with regulatory expectations.

Fully Humanized CAR Design

Engineered with a humanized Anti-CD19 scFv to enhance safety, specificity, and therapeutic durability.

Next-Generation CAR Architecture

Utilizes second-generation signaling domains optimized for controlled immune activation and efficacy.

Automated, Scalable Manufacturing

Produced using modular and automated systems designed for consistency, quality, and clinical scalability.

Clinical-Stage Development

Advancing through regulatory pathways as a lead clinical candidate focused on unmet patient needs.

Patients Served

0 k+

From Innovation to Clinical Impact

GX-01, also known as Ariflex, is currently progressing through regulatory approval processes as a clinical-stage candidate. Ongoing development is focused on demonstrating safety, efficacy, and manufacturability to support future clinical evaluation.

Discover & Design

We apply deep scientific expertise and intelligent engineering to design precise, next-generation cell and gene therapies.

01

Develop & Validate

Our programs advance through rigorous development, validation, and automation to ensure safety, quality.

02

Manufacture & Deliver

Using modular and automated manufacturing systems, we produce clinically ready therapies aligned with regulatory.

03 Bridging the gap between discovery and the clinic.

Partner with GenetiX to leverage our Nobel-prize-winning foundations and GMP-grade expertise. Let’s accelerate the next generation of life-changing therapies together.